Company news
OPKO Health, Inc. news in 2022
OPKO Health, Inc.'s news releases, calls and decks from 2022, newest first.
OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results
November 7, 2022
OPKO Health to Report Third Quarter 2022 Financial Results on November 8, 2022
October 31, 2022
OPKO Health Announces Leadership Changes for BioReference Laboratories
August 15, 2022
OPKO Health Reports 2022 Second Quarter Business Highlights and Financial Results
August 3, 2022
OPKO Health to Report Second Quarter 2022 Financial Results on August 4, 2022
July 24, 2022
OPKO Health to Present at the 2022 Jefferies Healthcare Conference
June 1, 2022
OPKO Health Reports 2022 First Quarter Business Highlights and Financial Results
May 8, 2022
OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases
May 8, 2022
OPKO Health to Report First Quarter 2022 Financial Results on May 9, 2022
May 4, 2022
GeneDx Announces Discovery of 200 New and Expanded Genetic Conditions
March 15, 2022
Saol Therapeutics and GeneDx, Inc. Collaborate to Detect Patients with Rare Mitochondrial Disease
February 28, 2022
OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results
February 23, 2022
OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022
February 16, 2022
Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency
February 14, 2022
RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP
February 2, 2022
Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
January 20, 2022
Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency
January 19, 2022
OPKO Health to Participate in the 40th Annual J.P. Morgan Healthcare Conference
January 4, 2022